San Francisco, California, December 23, 2009 – Jennerex Biotherapeutics, a clinical-stage biotherapeutics company developing a proprietary breakthrough class of targeted oncolytic virus therapeutics, today announced that management will present at the following upcoming investor conferences.

Biotech Showcase 2010
Tuesday, January 12, 2010
9:40 a.m. PT
Marines’ Memorial Club and Hotel, San Francisco

OneMedForum 2010
Wednesday, January 13, 2010
2:40 p.m. PT
Sir Francis Drake Hotel, San Francisco

Jennerex is a clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The company’s lead product JX-594, currently in an international Phase 2 trial for primary liver cancer and colorectal cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common cancers. Jennerex’s products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company’s poxviruses in cancer cells. These products simultaneously stimulate the body's immune response to the cancer. Of note, this mechanism of action and the results in patients to date put the company’s product class in a leadership position. Jennerex’s therapeutic approach is markedly different from gene therapy and standard cancer vaccine approaches. Jennerex Biotherapeutics was established in San Francisco CA and in Ottawa Canada in 2006 with Dr. David Kirn (CEO) in San Francisco and Dr. John Bell (CSO) from the Ottawa Health Research Institute/University of Ottawa. For more information about Jennerex and the company’s robust pipeline and three clinical-stage products, please visit www.jennerex.com.

Contact:
Jennifer Cook Williams
Cook Williams Communications, Inc.
(360) 668-3701
jennifer@cwcomm.org